BACKGROUND AND OBJECTIVES: Cardiovascular disease is prevalent in chronic kidney disease (CKD). Uric acid is increased in subjects with CKD and has been linked with cardiovascular mortality in this population. However, no study has evaluated the relationship of uric acid with angiographically proven coronary artery disease (CAD) in this population. We therefore investigated the link between serum uric acid (SUA) levels and (i) extent of CAD assessed by the Gensini score and (ii) inflammatory parameters, including C-reactive protein (CRP) and pentraxin-3, in patients with mild-to-moderate CKD. MATERIAL AND METHODS: In an unselected population of 130 patients with estimated glomerular filtration rate (eGFR) between 90 and 30 ml/min/1.73 m(2), we measured SUA, serum pentraxin-3, CRP, urinary protein-to-creatinine ratio, lipid parameters and the severity of CAD as assessed by coronary angiography and quantified by the Gensini lesion severity score. RESULTS: The mean serum values for SUA, pentraxin-3 and CRP in the entire study population were 5.5 ± 1.5 mg/dl, 6.4 ± 3.4 ng/ml and 3.5 ± 2.6 mg/dl, respectively. The Gensini scores significantly correlated in univariate analysis with gender (R = -0.379, p = 0.02), uric acid (R = 0.42, p = 0.001), pentraxin-3 (R = 0.54, p = 0.001), CRP (R = 0.29, p = 0.006) levels, eGFR (R = -0.33, p = 0.02), proteinuria (R = 0.21, p = 0.01), and presence of hypertension (R = 0.37, p = 0.001), but not with smoking status, diabetes mellitus, and lipid parameters. After adjustments for traditional cardiovascular risk factors, only uric acid (R = 0.21, p = 0.02) and pentraxin-3 (R = 0.28, p = 0.01) remained significant predictors of the Gensini score. CONCLUSIONS: SUA and pentraxin-3 levels are independent determinants of severity of CAD in patients with mild-to-moderate CKD. We recommend a clinical trial to determine whether lowering uric acid could prevent progression of CAD in patients with CKD.
BACKGROUND AND OBJECTIVES:Cardiovascular disease is prevalent in chronic kidney disease (CKD). Uric acid is increased in subjects with CKD and has been linked with cardiovascular mortality in this population. However, no study has evaluated the relationship of uric acid with angiographically proven coronary artery disease (CAD) in this population. We therefore investigated the link between serum uric acid (SUA) levels and (i) extent of CAD assessed by the Gensini score and (ii) inflammatory parameters, including C-reactive protein (CRP) and pentraxin-3, in patients with mild-to-moderate CKD. MATERIAL AND METHODS: In an unselected population of 130 patients with estimated glomerular filtration rate (eGFR) between 90 and 30 ml/min/1.73 m(2), we measured SUA, serum pentraxin-3, CRP, urinary protein-to-creatinine ratio, lipid parameters and the severity of CAD as assessed by coronary angiography and quantified by the Gensini lesion severity score. RESULTS: The mean serum values for SUA, pentraxin-3 and CRP in the entire study population were 5.5 ± 1.5 mg/dl, 6.4 ± 3.4 ng/ml and 3.5 ± 2.6 mg/dl, respectively. The Gensini scores significantly correlated in univariate analysis with gender (R = -0.379, p = 0.02), uric acid (R = 0.42, p = 0.001), pentraxin-3 (R = 0.54, p = 0.001), CRP (R = 0.29, p = 0.006) levels, eGFR (R = -0.33, p = 0.02), proteinuria (R = 0.21, p = 0.01), and presence of hypertension (R = 0.37, p = 0.001), but not with smoking status, diabetes mellitus, and lipid parameters. After adjustments for traditional cardiovascular risk factors, only uric acid (R = 0.21, p = 0.02) and pentraxin-3 (R = 0.28, p = 0.01) remained significant predictors of the Gensini score. CONCLUSIONS:SUA and pentraxin-3 levels are independent determinants of severity of CAD in patients with mild-to-moderate CKD. We recommend a clinical trial to determine whether lowering uric acid could prevent progression of CAD in patients with CKD.
Authors: Michael S Rolph; Sabine Zimmer; Barbara Bottazzi; Cecilia Garlanda; Alberto Mantovani; Göran K Hansson Journal: Arterioscler Thromb Vasc Biol Date: 2002-05-01 Impact factor: 8.311
Authors: Mohamed E Suliman; Richard J Johnson; Elvia García-López; A Rashid Qureshi; Hadi Molinaei; Juan Jesús Carrero; Olof Heimbürger; Peter Bárány; Jonas Axelsson; Bengt Lindholm; Peter Stenvinkel Journal: Am J Kidney Dis Date: 2006-11 Impact factor: 8.860
Authors: S M Kurt Lee; Andrew L Lee; Thomas J Winters; Emily Tam; Mohammed Jaleel; Peter Stenvinkel; Richard J Johnson Journal: Am J Nephrol Date: 2008-08-11 Impact factor: 3.754
Authors: Magdalena Madero; Mark J Sarnak; Xuelei Wang; Tom Greene; Gerald J Beck; John W Kusek; Allan J Collins; Andrew S Levey; Vandana Menon Journal: Am J Kidney Dis Date: 2009-03-20 Impact factor: 8.860
Authors: Mehmet Kanbay; Baris Afsar; Dimitrie Siriopol; Hilmi Umut Unal; Murat Karaman; Mutlu Saglam; Tayfun Eyileten; Mustafa Gezer; Samet Verim; Yusuf Oguz; Abdulgaffar Vural; Alberto Ortiz; Richard J Johnson; Adrian Covic; Mahmut Ilker Yilmaz Journal: Int Urol Nephrol Date: 2016-03-23 Impact factor: 2.370
Authors: Aslihan Yerlikaya; Tuncay Dagel; Christopher King; Masanari Kuwabara; Miguel A Lanaspa; Ana Andres-Hernando; Adrian Covic; Jacek Manitius; Alan A Sag; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2017-02-16 Impact factor: 2.370
Authors: Baris Afsar; Alan A Sag; Cinar Oztosun; Masanari Kuwabara; Mario Cozzolino; Adrian Covic; Mehmet Kanbay Journal: J Nephrol Date: 2019-04-27 Impact factor: 3.902
Authors: Aline Milane; Georges Khazen; Nabil Zeineddine; Mazen Amro; Leila Masri; Michella Ghassibe-Sabbagh; Sonia Youhanna; Angelique K Salloum; Marc Haber; Daniel E Platt; Jean-Baptiste Cazier; Raed Othman; Samer Kabbani; Hana Sbeite; Youssef Chami; Elie Chammas; Hamid El Bayeh; Dominique Gauguier; Antoine B Abchee; Pierre Zalloua; Antoine Barbari Journal: Int J Clin Exp Med Date: 2015-09-15
Authors: Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay Journal: J Sex Med Date: 2013-09-25 Impact factor: 3.802